Benefits of global mutant huntingtin lowering diminish over time in a Huntington's disease mouse model.

Autor: Marchionini DM; CHDI Management/CHDI Foundation, New York, New York, USA., Liu JP; University of Virginia School of Medicine, Charlottesville, Virginia, USA., Ambesi-Impiombato A; Psychogenics Inc., Paramus, New Jersey, USA., Kerker K; Psychogenics Inc., Paramus, New Jersey, USA., Cirillo K; Psychogenics Inc., Paramus, New Jersey, USA., Bansal M; Psychogenics Inc., Paramus, New Jersey, USA., Mushlin R; Psychogenics Inc., Paramus, New Jersey, USA., Brunner D; Psychogenics Inc., Paramus, New Jersey, USA., Ramboz S; Psychogenics Inc., Paramus, New Jersey, USA., Kwan M; Psychogenics Inc., Paramus, New Jersey, USA., Kuhlbrodt K; Evotec SE, Hamburg, Germany., Tillack K; Evotec SE, Hamburg, Germany., Peters F; Evotec SE, Hamburg, Germany., Rauhala L; Charles River, Kuopio, Finland., Obenauer J; Rancho Biosciences, San Diego, California, USA., Greene JR; Rancho Biosciences, San Diego, California, USA., Hartl C; Rancho Biosciences, San Diego, California, USA., Khetarpal V; CHDI Management/CHDI Foundation, New York, New York, USA., Lager B; CHDI Management/CHDI Foundation, New York, New York, USA., Rosinski J; CHDI Management/CHDI Foundation, New York, New York, USA., Aaronson J; CHDI Management/CHDI Foundation, New York, New York, USA., Alam M; CHDI Management/CHDI Foundation, New York, New York, USA., Signer E; CHDI Management/CHDI Foundation, New York, New York, USA., Muñoz-Sanjuán I; CHDI Management/CHDI Foundation, New York, New York, USA., Howland D; CHDI Management/CHDI Foundation, New York, New York, USA., Zeitlin SO; University of Virginia School of Medicine, Charlottesville, Virginia, USA.

Publikováno v: JCI insight [JCI Insight] 2022 Oct 24; Vol. 7 (20). Date of Electronic Publication: 2022 Oct 24.

Phylogenetic Characterization of Novel Reassortant 2.3.4.4b H5N8 Highly Pathogenic Avian Influenza Viruses Isolated from Domestic Ducks in Egypt During the Winter Season 2021–2022.

Autor: Saad, Noha^1,2 (AUTHOR) momtaz.shahein@yahoo.com, Esaki, Mana^3,4 (AUTHOR) k0068103@kadai.jp, Kojima, Isshu^3,4 (AUTHOR) i-kojima@ous.ac.jp, Khalil, Ahmed Magdy^3,5,6 (AUTHOR) ahmed.magdy.am549@gmail.com, Osuga, Shiori³ (AUTHOR) shiorin_birdie@yahoo.co.jp, Shahein, Momtaz A.^1,2 (AUTHOR), Okuya, Kosuke^3,4,7 (AUTHOR) kokuya@vet.kagoshima-u.ac.jp, Ozawa, Makoto^3,7 (AUTHOR) mozawa@vet.kagoshima-u.ac.jp, Alhatlani, Bader Y.⁸ (AUTHOR) nohapoultry@yahoo.com

Publikováno v: Viruses (1999-4915). Nov2024, Vol. 16 Issue 11, p1655. 22p.

Regionalization of the Mortality Risk from Cardiomyopathy and Respiratory Diseases Based on the Maximum Entropy Model.

Autor: Ordoñez-Sierra, Raymundo^1,2 (AUTHOR), Domínguez-Cortinas, Gabriela³ (AUTHOR), Hernández-Paniagua, Iván Yassmany⁴ (AUTHOR), Expósito-Castillo, José Luis¹ (AUTHOR), Gómez-Albores, Miguel A.¹ (AUTHOR) magomeza@uaemex.mx, Rodríguez-Reyes, María Guadalupe² (AUTHOR), Carrasco-Gallegos, Brisa Violeta² (AUTHOR), Manzano-Solís, Luis Ricardo² (AUTHOR), Santangelo, Omar Enzo (AUTHOR)

Publikováno v: Global Health, Epidemiology & Genomics. 8/20/2024, Vol. 2024, p1-13. 13p.

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.

Autor: Walker BA; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA., Mavrommatis K; Celgene Corporation, San Francisco, CA, USA., Wardell CP; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA., Ashby TC; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA., Bauer M; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA., Davies F; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA., Rosenthal A; Cancer Research and Biostatistics, Seattle, WA, USA., Wang H; Cancer Research and Biostatistics, Seattle, WA, USA., Qu P; Cancer Research and Biostatistics, Seattle, WA, USA., Hoering A; Cancer Research and Biostatistics, Seattle, WA, USA., Samur M; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Towfic F; Celgene Corporation, Summit, NJ, USA., Ortiz M; Celgene Institute of Translational Research Europe, Sevilla, Spain., Flynt E; Celgene Corporation, Summit, NJ, USA., Yu Z; Celgene Corporation, Summit, NJ, USA., Yang Z; Celgene Corporation, Summit, NJ, USA., Rozelle D; Rancho BioSciences, San Diego, CA, USA., Obenauer J; Rancho BioSciences, San Diego, CA, USA., Trotter M; Celgene Institute of Translational Research Europe, Sevilla, Spain., Auclair D; Multiple Myeloma Research Foundation, Norwalk, CT, USA., Keats J; Translational Genomics Research Institute, Phoenix, AZ, USA., Bolli N; University of Milan, Milano, Italy., Fulciniti M; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Szalat R; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Moreau P; University of Nantes, Nantes, France., Durie B; Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA, USA., Stewart AK; Department of Hematology, Mayo Clinic, Scottsdale, AZ, USA., Goldschmidt H; Department of Medicine V, Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany., Raab MS; Department of Medicine V, Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Heidelberg, Germany., Einsele H; Department of Internal Medicine II, Wurzburg University, Wurzburg, Germany., Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., San Miguel J; Clinica Universidad de Navarra, Centro Investigacion Medica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain., Lonial S; Winship Cancer Institute, Emory University, Atlanta, GA, USA., Jackson GH; Department of Haematology, Newcastle University, Newcastle, UK., Anderson KC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Avet-Loiseau H; Centre de Recherche en Cancérologie de Toulouse Institut National de la Santé et de la Recherche Médicale, U1037, Toulouse, France.; L'Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire, Toulouse, France., Munshi N; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Thakurta A; Celgene Corporation, Summit, NJ, USA., Morgan G; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA. GJMorgan@uams.edu.

Publikováno v: Leukemia [Leukemia] 2019 Jan; Vol. 33 (1), pp. 159-170. Date of Electronic Publication: 2018 Jul 02.

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

Autor: Walker BA; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR., Mavrommatis K; Celgene Corporation, San Francisco, CA., Wardell CP; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR., Ashby TC; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR., Bauer M; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR., Davies FE; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR., Rosenthal A; Cancer Research and Biostatistics, Seattle, WA., Wang H; Cancer Research and Biostatistics, Seattle, WA., Qu P; Cancer Research and Biostatistics, Seattle, WA., Hoering A; Cancer Research and Biostatistics, Seattle, WA., Samur M; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Towfic F; Celgene Corporation, Summit, NJ., Ortiz M; Celgene Institute of Translational Research Europe, Sevilla, Spain., Flynt E; Celgene Corporation, Summit, NJ., Yu Z; Celgene Corporation, Summit, NJ., Yang Z; Celgene Corporation, Summit, NJ., Rozelle D; Rancho BioSciences, San Diego, CA., Obenauer J; Rancho BioSciences, San Diego, CA., Trotter M; Celgene Institute of Translational Research Europe, Sevilla, Spain., Auclair D; Multiple Myeloma Research Foundation, Norwalk, CT., Keats J; Translational Genomics Research Institute, Phoenix, AZ., Bolli N; Department of Oncology, University of Milan, Milan, Italy., Fulciniti M; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Szalat R; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Moreau P; Department of Hematology, University of Nantes, Nantes, France., Durie B; Cedars-Sinai Samuel Oschin Cancer Center, Los Angeles, CA., Stewart AK; Department of Hematology, Mayo Clinic, Scottsdale, AZ., Goldschmidt H; Department of Medicine V, Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany., Raab MS; Department of Medicine V, Hematology and Oncology, University Hospital of Heidelberg, Heidelberg, Germany.; German Cancer Research Center, Heidelberg, Germany., Einsele H; Department of Internal Medicine II, Wurzburg University, Wurzburg, Germany., Sonneveld P; Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., San Miguel J; Centro Investigacion Medica Aplicada, Clinica Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra, Centro de Investigación Biomédica en Red de Oncología, Pamplona, Spain., Lonial S; Winship Cancer Institute, Emory University, Atlanta, GA., Jackson GH; Department of Haematology, Newcastle University, Newcastle, United Kingdom., Anderson KC; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Avet-Loiseau H; Centre de Recherche en Cancérologie de Toulouse Institut National de la Santé et de la Recherche Médicale U1037, Toulouse, France; and.; L'Institut Universitaire du Cancer de Toulouse Oncopole, Centre Hospitalier Universitaire, Toulouse, France., Munshi N; Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA., Thakurta A; Celgene Corporation, Summit, NJ., Morgan GJ; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR.

Publikováno v: Blood [Blood] 2018 Aug 09; Vol. 132 (6), pp. 587-597. Date of Electronic Publication: 2018 Jun 08.